iOnctura
Developing pipeline of drug candidates targeting immunosuppression in the tumor microenvironment.
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | €80.0m | Series B | |
| Total Funding | 000k | ||
Related Content
Notes (0)
More about iOnctura
EditDeveloper of next-generation bio-molecules intended for the treatment of cancer and fibrosis. The company's bio-molecules include novel therapeutics that modulate key culprits of immunosuppression in the tumor microenvironment, enabling doctors to treat diseases such as cancer faster.
Keywords: Healthcare Devices, Services, Supplies, Biomolecule Drugs, Biopharmaceutical Research, Cancer Drug, Cancer Treatment, Fibrotic Diseases Drugs, Oncology Treatment.
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.